Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $7M fell 33.3% year over year, ahead of the -37.6% change in trailing-twelve-month research & development. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at -19.5% a year.
Context
- Research & development amounted to 47.9% of revenue in FY2025.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -37.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 33.56M USD
- Year-over-year change
- -34.6%
- 4-year CAGR
- -23.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.56M | -34.6% |
| FY2024 | 2024-12-31 | 51.31M | -12.9% |
| FY2023 | 2023-12-31 | 58.91M | -8.6% |
| FY2022 | 2022-12-31 | 64.44M | -33.5% |
| FY2021 | 2021-12-31 | 96.83M | — |
Research & Development vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.6% is the 10th highest of 11, against a peer median of -15.1%.
- Over three fiscal years its annual growth of -19.5% compares with a peer median of +1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B USD | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $94.52M USD | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M USD | -20.8% | -13.4% | 131.9% | |
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $82.1M USD | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $62.37M USD | -24.6% | -10.1% | 27721.8% | |
| LTM Mar 2026 | $57.75M USD | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
| LTM Mar 2026 | $30.06M USD | -37.6% | -19.5% | — | |
| LTM Mar 2026 | $26.43M USD | -28.8% | -2.5% | 181.7% | |
| LTM Mar 2026 | $205K USD | -48.5% | -58.6% | 0.4% | |
| Peer median (excluding BDTX) | — | -15.1% | +1.3% | 567.3% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.